相关实验视频

Updated: Jan 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

对老年人高级非小细胞肺癌的第一线免疫疗法的回顾性研究

Sheng Yang^1,2,3,4, Yalin Zhu^1,2,3,4, Sitong Liu^1,2,3,4

¹Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital Central South University Changsha Hunan China.

Aging medicine (Milton (N.S.W))

|January 14, 2026

概括

年龄不是先进非小细胞肺癌 (NSCLC) 一线免疫治疗的显著预后因素. 良好的结果与吸烟状况,骨转移,PD-L1表达和预后营养指数 (PNI) 有关,pembrolizumab和tislelizumab加化疗方案之间没有显著差异.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
临床研究临床研究

背景情况:

先进的非小细胞肺癌 (NSCLC) 治疗通常涉及一线免疫疗法 (IO).
了解年龄和特定生物标志物对治疗结果的影响对于个性化医学至关重要.

研究的目的:

为了比较一线IO在老年人中的疗效和安全性,与晚期NSCLC的非老年患者相比.
确定与整体存活率 (OS) 相关的血液学生物标志物.
为了比较pembrolizumab加化学疗法 (CT) 与tislelizumab加CT在先进的NSCLC中.

主要方法:

对298名接受一线IO治疗的晚期NSCLC患者的回顾性分析.
老年人 (≥65岁) 和非老年人 (<65岁) 组的比较,包括老年人子组.
倾向分数匹配 (PSM) 来比较pembrolizumab+CT与tislelizumab+CT的疗效和安全性.

主要成果:

不同年龄组之间的OS没有统计学上显著的差异 (p=0.100).
对OS的独立预后因素包括吸烟史,骨转移,PD-L1 TPS和PNI.
血液学生物标志物如单细胞计数,NLR,PLR,MLR,PIV和SII与OS负相关,而PNI与OS正相关.
在pembrolizumab+CT和tislelizumab+CT组之间,在PSM前 (p=0.287) 和后 (p=0.346) 的中位 OS (mOS) 没有显著差异.

结论:

年龄不是先进NSCLC中一线IO的主要预后因素.
非吸烟者,没有骨转移的患者,高PD-L1 TPS (≥50%) 和高PNI显示了改善的OS.
布罗利祖马布加CT和tislelizumab加CT在高级NSCLC中显示出可比的疗效和安全性.

关键词:

年长的老人老年人老年人.老年人的医疗服务免疫检查点抑制剂免疫检查点抑制剂非小细胞肺癌的肺癌.这就是Pembrolizumab.这样一来,我们就有了Tislelizumab.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...